Improved in vivo delivery of m-THPC via pegylated liposomes for use in photodynamic therapy.

Abstract

Pegylated liposomal nanocarriers have been developed with the aim of achieving improved uptake of the clinical PDT photosensitiser, m-THPC, into target tissues through increased circulation time and bioavailability. This study investigates the biodistribution and PDT efficacy of m-THPC in its standard formulation (Foscan®) compared to m-THPC incorporated in… (More)
DOI: 10.1016/j.jconrel.2011.09.085

Topics

Cite this paper

@article{Bovis2012ImprovedIV, title={Improved in vivo delivery of m-THPC via pegylated liposomes for use in photodynamic therapy.}, author={Melissa J Bovis and Josephine H. Woodhams and Marilena Loizidou and Dietrich Scheglmann and Stephen G. Bown and Alexander J. Macrobert}, journal={Journal of controlled release : official journal of the Controlled Release Society}, year={2012}, volume={157 2}, pages={196-205} }